Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-TRUST: Ultra Short All Oral Regimen for MDR-TB
NCT03867136Phase 4Completed
- Sponsor
- Huashan Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of levofloxacin, linezolid, d-cycloserine, pyrazinamide, clofazimine in multidrug-resistant tuberculosis (MDR-TB), sponsored by Huashan Hospital. Started Jun 2020; status: completed.
02
Drugs
levofloxacinlinezolidd-cycloserinepyrazinamideclofazimine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03867136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867136.